1. Effect of oral niacin on central retinal vein occlusion
- Author
-
Sam E. Mansour, Janet L. Alexander, Ehsan Rahimy, Michael W. Gaynon, and Yannis M. Paulus
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,Retinal Vein ,Visual acuity ,genetic structures ,Fundus Oculi ,Vasodilator Agents ,Visual Acuity ,Administration, Oral ,030204 cardiovascular system & hematology ,Niacin ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,Central retinal vein occlusion ,Ophthalmology ,Retinal Vein Occlusion ,medicine ,Humans ,Macula Lutea ,Prospective Studies ,Fluorescein Angiography ,Prospective cohort study ,Macular edema ,Aged ,Aged, 80 and over ,Dose-Response Relationship, Drug ,medicine.diagnostic_test ,business.industry ,Middle Aged ,medicine.disease ,Fluorescein angiography ,eye diseases ,Sensory Systems ,Treatment Outcome ,Anesthesia ,030221 ophthalmology & optometry ,Female ,medicine.symptom ,business ,Tomography, Optical Coherence ,Dyslipidemia ,Follow-Up Studies - Abstract
Niacin, a treatment for dyslipidemia, is known to induce vasodilation as a secondary effect. Previous instances of patients with chronic central retinal vein occlusion (CRVO) and cystoid macular edema (CME) have been observed to spontaneously improve when placed on systemic niacin for hypercholesterolemia. The purpose of this study was to evaluate the effects of niacin on CRVO and associated ocular complications. A prospective, single-center, non-randomized, interventional case series of niacin for CRVO was conducted. Best-correct visual acuity (BCVA), central macular thickness (CMT), and ocular complications were analyzed in 50 patients over 1 year. Eight patients were controls. The mean initial logMAR BCVA was 0.915, and improved with niacin to 0.745 (P = 0.12), 0.665 (P = 0.02) and 0.658 (P = 0.03) after 3, 6, and 12 months of follow-up, respectively. At baseline, mean CMT was 678.9 μm, and improved to 478.1 μm (P = 0.001), 388.6 μm (P
- Published
- 2017